Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Interactions Between Signaling Pathways

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Depletion of extracellular asparagine impairs self-reactive T cells and ameliorates autoimmunity in a murine model of multiple sclerosis.

eLife·2026

Same author

Discovery of Tcf7 regulators with clonally-resolved CRISPR screens identifies Trim28 as a mediator of CD8 T cell differentiation in tumors.

bioRxiv : the preprint server for biology·2026

Same author

Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Selective depletion of virus-specific CD8 T cells from the liver after PD-1 therapy with Fc-intact antibody during chronic infection.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 Immunotherapy.

bioRxiv : the preprint server for biology·2026

Same author

Stability and progressive differentiation of T<sub>FR</sub> cells are intrinsically and extrinsically controlled by T<sub>FH</sub> programs.

Nature immunology·2026

Search research articles

Related Experiment Video

Updated: Sep 12, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

THE BIOLOGY BEHIND PD-1 CHECKPOINT BLOCKADE.

Arlene H Sharpe¹

¹Boston, MA.

Transactions of the American Clinical and Climatological Association

|August 7, 2025

Summary

New CRISPR screening platforms identify novel targets to enhance anti-tumor immunity, complementing programmed death 1 (PD-1) pathway inhibitors for improved cancer therapy. These tools enable gene discovery in immune cells without manipulation, advancing cancer treatment strategies.

Area of Science:

Immunology
Genetics
Oncology

Background:

Programmed death 1 (PD-1) pathway inhibitors have revolutionized cancer therapy, but limited patient response necessitates new therapeutic targets.
Identifying novel regulators of anti-tumor immunity is crucial to enhance the efficacy of current immunotherapies.

Purpose of the Study:

To develop and utilize innovative in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based screening platforms.
To discover novel regulators of anti-tumor immunity that can complement PD-1 blockade therapy.

Main Methods:

Development of CRISPR-based platforms for gene screening in mature immune cell lineages.
Implementation of gene perturbation techniques without immune cell stimulation or manipulation to preserve cell function.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Related Experiment Videos

Last Updated: Sep 12, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Application of these platforms to identify new targets promoting anti-tumor immunity.

Main Results:

The study introduces novel CRISPR screening platforms for immune cell research.
These platforms facilitate the discovery of previously unknown regulators of anti-tumor immune responses.
The identified targets hold potential for developing more effective cancer therapies.

Conclusions:

The developed CRISPR platforms offer innovative approaches for discovering therapeutic targets in cancer immunology.
These findings pave the way for next-generation cancer immunotherapies that overcome resistance to PD-1 blockade.
Further research utilizing these platforms can significantly advance the field of immuno-oncology.